BCIQ Profiles

Company Profile Report

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

The BLyS inhibitor could become the first drug for lupus nephritis, which affects about 1 million patients

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis.

Richard Furie, the lead investigator of the BLISS-LN trial, told BioCentury that although lupus nephritis is a complication of systemic lupus

Read the full 496 word article

How to gain access

Continue reading with a
two-week free trial.